TelomEye is a pioneering biopharmaceutical company dedicated to saving sight and revolutionizing eye care through transformative science. We are motivated by the millions affected by age-related eye diseases, driving us to develop breakthrough therapies that address unmet medical needs in ophthalmology and enhance patients’ quality of life.

Our journey began in 2017 in Istanbul, when ophthalmologist Dr. İskender Alkın Solmaz recognized the potential of telomere biology to combat presbyopia and other vision-threatening conditions. Building on the Nobel Prize-winning discovery of telomeres’ role in cellular aging, Dr. Solmaz and his team developed a novel approach: topical treatments, like eye drops, that could target aging eye tissues directly while minimizing systemic risks.

Since our founding in 2021 in Toronto, TelomEye has advanced a highly differentiated pipeline, leveraging proprietary formulations and rigorous science. Our lead program targets Fuchs’ Endothelial Corneal Dystrophy (FED), a progressive disease affecting 4% of the population, with the potential to slow or halt its progression—offering an alternative to invasive procedures like corneal transplantation.

Our milestones include securing $1 million in funding at a $10 million valuation, joining JLab Toronto’s prestigious biotech hub, and earning the “Most Inspiring Presentation” award at the 2024 Bio NJ conference from J.P. Morgan and Johnson & Johnson. Today, we are preparing for human trials in early 2026, with a goal to bring our groundbreaking treatment to market by 2027-2028.

TelomEye isn’t just developing a therapy—we’re building a future where vision loss is no longer inevitable.